IMVT
Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.45
+1.41%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 170.48x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 8.27x
- Price / sales
- 857.36x
- Price / cash flow
- -14.68x
Enterprise value
- Enterprise value
- $5.3B
- EV / sales
- 744.92x
- EV / EBITDA
- -9.81x
- EV / EBIT
- -9.46x
- Market cap
- $6.1B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026